FELIX Study Shows Obe-cel Has Tolerable Immunotoxicity Profile

By Leah Sherwood, Claire Roddie, MD, PhD - Last Updated: June 26, 2023

Claire Roddie, MD, PhD, a clinician-scientist at the University College London, discusses topline results from the pivotal FELIX study. The study evaluated the safety and efficacy of obecabtagene autoleucel (obe-cel), a CD19-directed autologous chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).

Dr. Roddie presented data from the FELIX study during the 2023 European Hematology Association Congress in Frankfurt, Germany.

“It’s been a great experience running this study and being able to deliver this really nice CAR T-cell therapy to so many adult patients with B-ALL,” Dr. Roddie said in her video interview with Blood Cancers Today. “We’ve got … robust manufacturing, [and] a great response rate, 76% (complete response rate), lots of those durable responses.”

The study showed that the infusion of obe-cel resulted in very low rates of grade 3 or higher cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.

“The immunotoxicity profile was tolerable, with very few grade 3 immunotoxic events and a nice persistence profile,” she said. “What this is telling us is that this … product lends itself very nicely to the adult ALL space. Even with … high-risk patients.”

Post Tags:EHA2023
Editorial Board